Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.
Sponsor: Janux Therapeutics
Summary
This first-in-human (FIH) study aims to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JANX011 dosed subcutaneously (and potentially intravenously) in healthy adult volunteers (HVs) to gain insight into its therapeutic utility in patients with autoimmune diseases.
Official title: A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of JANX011 With Optional Step-Up Dosing in Healthy Adult Volunteers
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-02
Completion Date
2026-12
Last Updated
2025-12-18
Healthy Volunteers
Yes
Conditions
Interventions
JANX011
JANX011 is administered subcutaneously, one time.
Locations (1)
CMAX
Adelaide, South Australia, Australia